<code id='0877BF6596'></code><style id='0877BF6596'></style>
    • <acronym id='0877BF6596'></acronym>
      <center id='0877BF6596'><center id='0877BF6596'><tfoot id='0877BF6596'></tfoot></center><abbr id='0877BF6596'><dir id='0877BF6596'><tfoot id='0877BF6596'></tfoot><noframes id='0877BF6596'>

    • <optgroup id='0877BF6596'><strike id='0877BF6596'><sup id='0877BF6596'></sup></strike><code id='0877BF6596'></code></optgroup>
        1. <b id='0877BF6596'><label id='0877BF6596'><select id='0877BF6596'><dt id='0877BF6596'><span id='0877BF6596'></span></dt></select></label></b><u id='0877BF6596'></u>
          <i id='0877BF6596'><strike id='0877BF6596'><tt id='0877BF6596'><pre id='0877BF6596'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:8
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs
          Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

          YichuanCao/SipaUSAviaAPImagesGileadSciencessaidMondaythatTrodelvy,its“smart-bomb”medicinethatcombine

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

          Whyarerichbiotechscuttingcosts?HasJPMWeekalreadywornoff?Andwhat’sgoingtomovemarketsin2024?Wecoverall